Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Three Dimension Tomography of Eye Structures by White Light Imaging Device (3D-WLT)

22 de abril de 2015 actualizado por: Avner Belkin, Meir Medical Center

The purpose of this study is to investigate the ability of an imaging device, developed by AdOM Advanced Optical Technologies Ltd. ("AdOM"). The device allows a three-dimensional imaging of the ocular tissues, specifically the tear film layers and the retinal layers. The device is based on the use of white light.

In this initial study, the device will be used to assess the tear film which coats the corneal surface in healthy subjects as well as in moderate-to-severe Keratoconjunctivitis Sicca (KCS) or Dry Eye Syndrome (DES). The ability of the device to assess the retinal layers will be evaluated in the second phase of the study.

Descripción general del estudio

Descripción detallada

The purpose of this study is to investigate the ability of an imaging device, developed by AdOM Advanced Optical Technologies Ltd. ("AdOM"). AdOM has produced an imaging device based on a standard fundus camera that uses white light, and as combined with new algorithms allows for a new reconstruction of three-dimensional images. The materials from which the Medical Instrumentation and Device are comprised are optical components (lenses), a broadband light source power, mechanical engines, beam splitters, and optical filters. The device will in addition contain camera sensors and a spectral detector. These elements are linked to a computer which includes control software and a user interface. The device allows a three-dimensional imaging of the ocular tissues, specifically the tear film layers and the retinal layers.

In this initial study, the device will be used to assess the tear film which coats the corneal surface in healthy subjects as well as in moderate-to-severe Keratoconjunctivitis Sicca (KCS) or Dry Eye Syndrome (DES). The ability of the device to assess the retinal layers will be evaluated in the second phase of the study.

The aqueous layer of the tear layer thickness is expected to be measured at an accuracy level of approximately one nanometer. All values will be measured over time and thus it will be possible to deduce the breakup time of the tear layer and the evaporation rate. It is possible that information will also be provided on the mucin layer and its level of sharpness.

Using the device will include the following steps:

  1. Resting the head and fixing it with the assistance of the chin and forehead rests.
  2. Locating and focusing the device on the cornea or retina with the help of the examiner.
  3. Identifying the retinal and vitreous layers and pressing to start measurement or, alternatively:
  4. Identifying the tear film layers and pressing to start the measurement.
  5. Pressing on the button to end the measurement. The expected measurement duration is 20 to 70 seconds. Analysis of the returned light will describe at each second the thickness of the layers and the continuity of the surface.

Study population:

A total of 20 healthy patients. A total of 40 adult male or female patients with moderate-to-severe KCS or DES.

Conduct of the Study:

This is a case-control, non-randomized observational study. The study will include two visits: a screening visit and a study visit.

During the screening visit the patients will sign the informed consent form and a full medical history will be recorded. All ocular signs and symptoms will be evaluated and a full biomicroscopic examination will be performed. Disease activity will be assessed using the Dry Eye Symptom Score (DESS), Schirmer Test (ST), tear meniscus height (TM), tear break-up time (BUT), and fluorescein staining (FS).

The second visit will be scheduled up to 4 weeks after the screening visit. During the second visit (the photography session), all ocular signs and symptoms will be evaluated and a full biomicroscopic examination will be performed. Disease activity will be assessed using the Dry Eye Symptom Score (DESS), Schirmer Test (ST), tear meniscus height (TM), tear break-up time (BUT), and fluorescein staining (FS).

The tear film layer will be photographed by the investigational device and the participation of the volunteers in the study will end with the end of the photography session.

Time frame: participants will be followed for the duration of their participation in the study which is expected to be up to 4 weeks.

Tipo de estudio

De observación

Inscripción (Anticipado)

60

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Noa Geffen, MD
  • Número de teléfono: +972-9-7472427
  • Correo electrónico: noatal1122@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

20 healthy subject with no ocular disease 40 subjects with moderate to severe keratoconjunctivitis sicca or dry eye syndrome

Descripción

Inclusion Criteria:

Age >/= 18 years Healthy controls - without dry eyes

Patients with a diagnosis of moderate-to-severe KCS as defined by all of the following:

  1. The presence of at least one ocular symptom of dryness scored at > 2 (where 0 = none and 4 = very severe /interferes with normal activities)
  2. Positive Schirmer test (ST without anesthesia) < 7 mm/5 min in either eye
  3. Positive fluorescein stainig (FS), defined as a corneal punctate fluorescein staining score of > 1 in either eye, where 0 = none and 3 = severe.

Exclusion Criteria:

  1. Stevens-Johnson Syndrome
  2. Post-burn ocular injury
  3. Chronic ocular disease other than KCS requiring topical treatment
  4. Ocular herpes simplex virus infection
  5. Use of contact lenses
  6. Persistent Intraocular Inflammation or Infection
  7. Active blepharitis of greater than mild degree
  8. Recent surgical occlusion of the lacrimal puncta
  9. Subepithelial cornea scarring
  10. Anesthetic or neurotrophic corneas.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Healthy subjects
None invasive imaging of the tear film for subjects with no eye disease
White light tomography imaging
keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)
None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
White light tomography imaging

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety (Ocular symptoms)
Periodo de tiempo: One month
Ocular symptoms, including - I. pain (graded as 0-none, 1- mild discomfort, 2-moderate pain, 3- severe pain, 4- very severe), II. burning (graded as 0-none, 1- mild , 2-moderate, 3- severe, 4- very severe), itching (graded as 0-none, 1- mild , 2-moderate, 3- severe, 4-very severe) 2. Red eye (graded as 0-none, 1- mild , 2-moderate, 3- severe, 4- very severe)
One month

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Imaging capabilities (field of view, resolution)
Periodo de tiempo: On sight
  1. field of view, measured in millimeters
  2. resolution measured in line per millimeters
On sight
Tear film measurements (lipid layer thickness, aqueous layer thickness)
Periodo de tiempo: on sight
  1. lipid layer thickness measured in microns
  2. aqueous layer thickness measured in microns
on sight

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Noa Geffen, MD, Meir Medical Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de abril de 2015

Finalización primaria (Anticipado)

1 de diciembre de 2015

Finalización del estudio (Anticipado)

1 de junio de 2016

Fechas de registro del estudio

Enviado por primera vez

1 de abril de 2015

Primero enviado que cumplió con los criterios de control de calidad

22 de abril de 2015

Publicado por primera vez (Estimar)

23 de abril de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

23 de abril de 2015

Última actualización enviada que cumplió con los criterios de control de calidad

22 de abril de 2015

Última verificación

1 de abril de 2015

Más información

Términos relacionados con este estudio

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir